New targeted drug T320 enters first human tests for advanced cancers
NCT ID NCT07434609
First seen Feb 27, 2026 · Last updated May 03, 2026 · Updated 8 times
Summary
This early-phase study tests a new drug, T320, in about 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if T320 can shrink tumors. Participants receive T320 every two weeks, and the study will monitor side effects and any anti-cancer activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR (PHASE 1) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.